SURF4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL16111548	1.00	2/20
SCHEMBL29931136	1.00	2/20
SCHEMBL4697866	0.89	2/20
SCHEMBL24532075	0.89	2/20
SCHEMBL4697696	0.86	2/20
SCHEMBL23092285	0.86	2/20
SCHEMBL29688472	0.86	2/20
SCHEMBL22024695	0.86	2/20
SCHEMBL22025026	0.82	2/20
SCHEMBL22119546	0.82	2/20
SCHEMBL22024561	0.81	2/20
SCHEMBL22025030	0.81	2/20
SCHEMBL24532038	0.81	2/20
SCHEMBL29728052	0.81	2/20
SCHEMBL22024567	0.81	2/20
SCHEMBL4699140	0.80	2/20
SCHEMBL22025313	0.80	2/20
SCHEMBL22025316	0.80	2/20
SCHEMBL23092264	0.80	2/20
SCHEMBL24532081	0.80	2/20

Clinical trials — most relevant to SURF4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.	PHASE3	RECRUITING
Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia	PHASE2/PHASE3	COMPLETED
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)	PHASE1/PHASE2	RECRUITING
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)	PHASE1/PHASE2	NOT_YET_RECRUITING
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
A Study of the Natural Course of SURF1 Deficiency	nan	WITHDRAWN
Genetic Regulation of Surfactant Deficiency	nan	COMPLETED
The preSPG4 Study - Studying the Prodromal and Early Phase of SPG4	nan	RECRUITING
Hydroxychloroquin (HCQ) in chILD of Genetic Defect	nan	COMPLETED
Consequences of Mutations in the SPG7 Gene at the Heterozygous State	nan	COMPLETED
Family Myopia Study	nan	COMPLETED
Molecular & Clinical Evaluation of Low HDL Syndromes	nan	COMPLETED
Molecular Genetic Epidemiology of Endocardial Cushion Defects - SCOR in Pediatric Cardiovascular Disease	nan	COMPLETED
Genetic and Epidemiologic Studies of Premature Coronary Artery Disease - SCOR in Arteriosclerosis	nan	COMPLETED
Genetic Causes and Clinical Features of Childhood Interstitial Lung Diseases in China	nan	COMPLETED
Identification of a New Gene Involved in Hereditary Lipodystrophy	nan	COMPLETED
Gene-Specific Responses to Exercise in Discordant Twins	nan	COMPLETED
Pharmacogenetics of Hypertriglyceridemia in Hispanics	nan	COMPLETED
The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy	nan	COMPLETED
Gene Modifiers of Cystic Fibrosis Lung Disease	nan	ACTIVE_NOT_RECRUITING
Hemochromatosis and Iron Overload Screening Study (HEIRS)	nan	COMPLETED
Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD	nan	COMPLETED
Modeling DNA Diversity in Reverse Cholesterol Transport	nan	COMPLETED
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)	nan	COMPLETED
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise	nan	COMPLETED
Health Improvements by Understanding the Determinants of Residual Risk in Coronary Artery Disease and New Targets for Prevention and Treatment	nan	RECRUITING
Heritage Study--Genetics, Exercise and Risk Factors	nan	COMPLETED
Implementation of Molecular Diagnostic Pathways	nan	UNKNOWN
Surfactant Derived Protocol in Heart Failure	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SURF4 binder may also engage these)

Protein	Name	Similarity
A7YY49	—	1.000	A7YY49 →
Q64310	—	1.000	Q64310 →
Q5R705	—	1.000	Q5R705 →
Q800K9	—	1.000	Q800K9 →
Q7SZQ7	—	1.000	Q7SZQ7 →
O57590	—	1.000	O57590 →
Q8R1Z9	—	0.934	Q8R1Z9 →
Q6P360	—	0.934	Q6P360 →
Q9P003	—	0.933	Q9P003 →
Q9H920	—	0.932	Q9H920 →
Q6DD32	—	0.931	Q6DD32 →
Q5RE33	—	0.930	Q5RE33 →
A2VE61	—	0.930	A2VE61 →
Q3T126	—	0.930	Q3T126 →
Q5RBJ7	—	0.929	Q5RBJ7 →
Q9CX13	—	0.928	Q9CX13 →
Q6GM44	—	0.928	Q6GM44 →
Q9BZW5	—	0.927	Q9BZW5 →
Q940S0	—	0.927	Q940S0 →
Q00765	—	0.927	Q00765 →
Q5R9K4	—	0.926	Q5R9K4 →
Q6P3N5	—	0.925	Q6P3N5 →
A6QL84	—	0.925	A6QL84 →
Q9IA05	—	0.925	Q9IA05 →
Q99KU0	—	0.925	Q99KU0 →
CDS2	Phosphatidate cytidylyltransferase 2	0.925	landscape →
Q9ZPS7	—	0.925	Q9ZPS7 →
Q9UGQ2	—	0.925	Q9UGQ2 →
Q5R9I4	—	0.924	Q5R9I4 →
B2RZ37	—	0.924	B2RZ37 →